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Abstract
Purpose: To evaluate the pathologic response of cervical carcinoma to external beam
radiotherapy (EBRT) and high dose rate brachytherapy (HDRB) and outcome.
Materials and methods: Between 1992 and 2001, 67 patients with cervical carcinoma were
submitted to preoperative radiotherapy. Sixty-five patients were stage IIb. Preoperative treatment
included 45 Gy EBRT and 12 Gy HDRB. Patients were submitted to surgery after a mean time of
82 days. Lymphadenectomy was performed in 81% of patients. Eleven patients with residual cervix
residual disease on pathological specimen were submitted to 2 additional insertions of HDRB.
Results: median follow up was 72 months. Five-year cause specific survival was 75%, overall
survival 65%, local control 95%. Complete pelvic pathological response was seen in 40%. Surgery
performed later than 80 days was associated with pathological response. Pelvic nodal involvement
was found in 12%. Complete pelvic pathological response and negative lymphnodes were
associated with better outcome (p = .03 and p = .005). Late grade 3 and 4 urinary and intestinal
adverse effects were seen in 12 and 2% of patients.
Conclusion: Time allowed between RT and surgery correlated with pathological response. Pelvic
pathological response was associated with improved outcome. Postoperative additional HDRB did
not improve therapeutic results. Treatment was well tolerated.
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Radiotherapy (RT), surgery (S), or the combination of
both treatments with preoperative radiotherapy following
surgery (RT→S) have all been shown to be effective local-
regional treatments [1-8] for patients with FIGO stages
IB1, IB2, IIA and IIB (with <1/3 proximal parametrial
invasion) cervix carcinoma [9,10]. Recent randomized tri-
als have demonstrated that the addition of chemotherapy
(CT) to RT improves treatment results [11,12]. The choice
of the best local-regional approach remains controversial.
Early retrospective reviews showed better results for
patients treated with hysterectomy following radiotherapy
for bulky cervical carcinoma [13,14]. O'Quim and cols
published special recommendations for hysterectomy fol-
lowing RT for bulky endocervical carcinoma [15], but
more recent randomized and retrospective studies have
failed to demonstrate better local control or survival with
such combined modality [3,16-18] and therefore RT→S
remains controversial.
Several factors have been associated with prognosis for
patients with cervical cancer treated with RT followed by
surgery: performance status, age, tumor size, FIGO stage,
residual tumor, histology, and nodal status [4,6,17,19].
There is no consensus on whether or not the presence of
residual tumor on hysterectomy specimens is related to
better survival and local control [4,6,17,19-21]. Few stud-
ies have evaluated the role of external beam radiation
therapy and brachytherapy with high dose rate (HDRB) as
a preoperative modality.
We performed a retrospective study to analyze the patho-
logic response and to relate it to survival in patients with
early stage cervical carcinoma (most initial IIB) submitted
to EBRT and HDRB following hysterectomy.
Materials and methods
Patients
from December 1992 to December 2001, 67 patients with
invasive cervical cancer were submitted in a single institu-
tion to hysterectomy following preoperative radiotherapy
with external beam irradiation and high dose rate brachy-
therapy. Chemotherapy was not administered to any of
them. Median age was 46 years (range 22–72). Squamous
cell carcinoma was the histological type in 56 patients
(84%); adenocarcinoma in 9 (13%); and 2 patients (3%)
had other histologies. Clinical staging of the tumor was
defined after clinical history and physical examination
performed at least by one gynecology oncologist surgeon
and one radiation oncologist. According to the 1995
FIGO staging system 65 patients (97%) were "early" IIB
(less than 1/3 proximal parametrial involvement), 1
(1.5%) was IIA and 1 (1.5%) was IB "bulky". All patients
were submitted to cistoscopy, rectosigmoidoscopy, rou-
tine blood count, and biochemical profile and chest radi-
ography. Abdominal-pelvic tomography was not
routinely used until 1996, when it was incorporated to
our staging routine for all patients. Patients' characteristics
are shown in Table 1.
Radiation therapy
all patients received preoperative treatment with EBRT
and reduced dose HDRB. Treatment with EBRT was deliv-
ered with 4 or 6 mV linear accelerators. Patients were
treated in prone position with 45 Gy in a four-field "box''
technique to the whole pelvis. All fields were treated daily.
Fractionation was 1.8 Gy per day five times per week.
Median dose with EBRT was 45 Gy (range 29–45 Gy) and
mean dose was 44.5 Gy. None of the patients received par-
ametrial boost.
After the second week of pelvic irradiation all patients
were submitted to a physical examination in order to eval-
uate the anatomical and geometrical conditions for brach-
ytherapy, and whenever possible, high dose rate
brachytherapy (HDRB) was started during EBRT. Intracav-
itary treatment (HDRB) was delivered with Fletcher after-
loading applicators with an Iridium-192 source (IR-192)
with a nominal activity of 10 Ci. Proposed dose to point
A was delivered in two weekly insertions of 6 Gy. The
median dose of brachytherapy to point A was 12 Gy
(range 6–15 Gy) and the mean point A dose was 11.8 Gy.
According to the beliefs of the assistant physician, 11
patients with residual tumor on cervix and no positive
margin on surgical specimens were submitted to postop-
erative vaginal vault HDRB with 12 Gy (2 fractions of 6
Gy) prescribed on the vaginal surface. Two other patients
who presented cervical complete pathological response
Table 1: Patient and treatment characteristics.
Median Range
Age 46 22 – 72
EBRT – Gy 45 29 – 45
HDRB – Gy 12 6 – 15
Radiotherapy duration – days 42 27 – 108
Delay to surgery – days 82 45 – 182
Absolute number %
Histological type
Squamous cell carcinoma 56 84%
Adenocarcinoma 9 13%
Other 2 3
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time to complete both EBRT and HDRB was 42 days
(range 27–108), and the mean time was 45 days.
Surgery
The surgical procedure was carried out in a median time
of 82 days (45 – 182) after the preoperative RT course
(including the preoperative HDRB insertions). The proce-
dure consisted of radical hysterectomy plus bilateral salp-
ingo-oophorectomy – Piver II type. Fifty-four patients
(81%) underwent selective pelvic lymph node dissection.
Pathologic examination
Pathologic response was evaluated in the surgical speci-
mens according the presence of residual tumor on the cer-
vix, paracervical tissues and pelvic lymph nodes.
Complete pathologic response (CPR) was defined as total
absence of residual disease.
Analysis of recurrent sites
Treatment failure was classified as local recurrence when
it ocurred in cervix, paracervical tissues or vaginal vault.
Whereas, local-regional recurrence when it occurred
inside the pelvis. Distant metastasis was defined as any
recurrence outside the pelvis.
Statistical analysis
The chi-square test was performed to evaluate significance
of variables. Kaplan-Meier test was used to calculate over-
all and specific survival. Univariate analysis was assessed
using the log-rank-test.
Analysis of complications
Complications were recorded for bladder, ureter, small
bowel, and rectum. All acute and late complications were
scored according to the Radiation Therapy Oncology
Group (RTOG) scale.
Results
Median follow-up time was 72 months (range 4 – 151).
Two patients (3%) were lost to follow-up. At the end of
this data collection, 41 patients (61%) were alive, of
whom 39 had no evidence of disease. Sixteen patients
(23%) died of cancer and 8 patients (12%) died of other
causes. Five-year overall survival (OS) was 65%, and 5-
year cause-specific survival (CSS) was 75% (Fig. 1a).
Local-regional recurrence occurred in 7 patients (10% – 3
local and 4 regional) and distant metastasis developed in
15 patients (22%). Five-year disease free survival (DFS),
Local control, local-regional control and distant control
were 75%, 95%, 90% and 79% (Fig. 1b).
Twenty-seven patients (40%) achieved pelvic complete
pathological response (pCPR) – no residual tumor on any
pathological specimen (cervix, parametrium and lymph
nodes, if available). Cervical complete pathological
response (cCPR) was found in 29 patients (43%). Para-
metrial CPR was achieved in all 65 patients with clinical
parametrial involvement.
Five-year DFS was higher for patients who achieved pCPR
(88% vs. 65%, p = 0.03). Also there was an advantage in
(a) Overall survival (OS) in 67 cervix cancer patients submitted to preoperative radiotherapyFigur  1
(a) Overall survival (OS) in 67 cervix cancer patients submitted to preoperative radiotherapy. (b) Disease free survival (DFS) of 
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nificant statistic difference in 5-year local-regional control
(96% vs. 86%, p = 0.3) (Fig. 2). Five-year overall and
cause-specific survival were better for patients who
achieved pCPR (72% vs. 54%, p = 0.06; and 86% vs. 63%
p = 0.02).
For 29 patients with cCPR no recurrences were seen while
for 38 patients with residual cervical tumors 3 recurrences
occurred. However, these numbers did not reach signifi-
cant level (p = 0.2). The 5-year OS, DFS, and CSS were
67% vs. 57% (p = 0.25), 82% vs. 69% (p = 0.19), and 85%
vs. 67%, (p = 0.15).
For 11 patients with residual cervical tumors submitted
postoperatively to vaginal vault HDRB there was one fail-
ure while for 27 patients with residual cervical cancer not
submitted to postoperative HDRB there were 2 failures
(10% vs. 7%; p = 0.97).
For the 54 patients submitted to lymphadenectomy (81%
of the cohort) the median and mean number of lymph
nodes dissected were 8 and 10 nodes respectively. Positive
lymph node involvement (N+) was found in 8 patients
(15%). Of 22 cCPR patients there were 2 N+ while among
35 patients with residual disease on the cervix there were
6 N+ (10 vs. 17%, p = 0.46). Lymph node involvement
was a strong predictor of prognosis. Five-year OS for N+
and N- patients was 37% vs. 71% (p = 0.01), and 5-year
CSS for N+ and N- patients was 46% vs. 78% (p = 0.01).
Also, the 5-year DFS (80% vs. 47%, p = 0.005), 5-year
metastasis free survival (84% vs. 47%; p = 0.0008) was
worse for N+ patients, but the postoperative N stage had
no impact on local regional control (93% vs. 87%; p =
0.57).
Median duration of radiotherapy was 42 days (range 27–
108), and there was no significant statistic correlation
between delay of irradiation and pathologic response on
prognosis.
Patients underwent surgery after a median interval after
radiotherapy of 82 days (range 45–182). When surgery
was performed earlier than 80 days there were signifi-
cantly less pCPR (22% vs. 57%; p = 0.003), and cCPR
(28% vs. 57%; p = 0.017).
Age and histological type were not associated with prog-
nosis or with better pathological response. (p = 0.3 and
0.14 respectively).
According to the RTOG morbidity scale there were 12%
grade 3 or 4 late genitourinary and 4.5% late gastrointes-
tinal sequelae. Table 2 shows the crude incidence of gas-
trointestinal and geniturinary complications.
Discussion
In the late 60's Durrance and cols published their analysis
of cervical cancer central recurrences from a retrospective
study conducted in the MDACC. They showed that after
radical radiotherapy the incidence of central recurrences
was higher in patients with bulky or barrel-shaped dis-
ease, and that local control could be improved with post
irradiation histerectomy. However, they have included
patients with extensive parametrial disease [14]. In the
mid 70's Rutledge and cols published another study, from
the same institution. This time excluding patients with
massive tumors, and confirmed the concept that the addi-
tion of post irradiation surgery to bulky disease patients
improved results in local control [13]. During this period,
in Europe, Pilleron and cols used this modality of treat-
ment published in the Institute Curie and showed worse
local regional and distant control in patients with residual
tumor after preoperative brachytherapy [22].
Based on these studies and in other smaller reports, Nel-
son and O'Quin introduced guidelines for hysterectomy
after irradiation [15,23]. Several institutions around the
world then adopted pre-operative irradiation as the stand-
ard treatment of bulky uterine cervical cancer and new
conflicting data began to appear.
In the late 80's the first drawback came when Perez and
cols published a prospective randomized trial and
described comparable results with either surgery follow-
ing radiotherapy or radiotherapy alone [24]. Perez had
shown in previews retrospective articles the same results
against the use of surgery after irradiation [3,4,18].
In a Radiation Therapy Oncology Group (RTOG 84/20)
and Gynecology Oncology Group (GOG) prospective ran-
domized trial comparing radiation therapy followed or
not by extra-facial hysterectomy there was a reduction in
pelvic recurrence and an increase in progression free sur-
vival for patients submitted to surgery after irradiation.
Residual disease on cervical specimen was a strong predic-
tor of disease progression and death [6].
In Brazil, a country with a high incidence of cervical can-
cer, pre-operative treatment is a common approach rec-
ommended by gynecologist surgeons. In part, due to the
idea that sexual function could be improved with surgery
[25].
Our study showed that pelvic radiotherapy followed by
high dose rate brachytherapy and hysterectomy yield a 5-
year OS of 63% and CSS of 73%. These results are similar
to our own experience with exclusive RT and to other pub-
lished data from other institutions [5,26-28].Page 4 of 8
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Survival in cervix cancer patients submitted to preoperative radiotherapy according to pathological pelvic responseFigure 2
Survival in cervix cancer patients submitted to preoperative radiotherapy according to pathological pelvic response. (a) Disease 
free survival. (b) Local-regional control. (c) Metastasis tree survival. (pCPR: pelvic complete pathological response)
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higher rates of toxicity than each modality alone [2,16],
but it is definitely not a consensus [2-4,6,18,24]. In the
RTOG 84/20 both RT alone and RT→S were well tolerated
producing similar rates of grade 3 or 4 adverse effects [6].
It is important to notice that the literature describes higher
rates of toxicities in patients submitted to radiotherapy
after surgery, and that most of the patients submitted to
surgery as a sole treatment in intent, will later need to be
irradiated as shown by Landoni and cols [5] who have
noticed that up to two thirds of patients submitted to sur-
gery will need adjuvant radiotherapy. In our study RTOG
grade 3 and 4 morbidity was rarely seen (genitourinary
9% and gastrointestinal 4%), and were comparable to
results of RT alone [6,24]. The incidence of toxicity may
also be dependent on total RT dose as the RTOG 84/20
and the current study has used lower brachytherapy doses.
There are a few reasons that may justify the use of post
irradiation surgery. They are mostly related to the accom-
plishment of the pathological staging of the tumor and to
the access of in vivo response to the previous treatment.
Lymph node metastases are known to carry a worse prog-
nosis before treatment [1,29-31]. They also carry a worse
prognosis if they remain affected after irradiation [4,6,19].
The evaluation of cervical residual disease also allow the
demonstration of tumor sensitivity to radiation and its
impact on treatment results [4,6,7,17,18,20,21,32,33].
Also, in the future with the study of genetic and bio-
molecular features it may be possible to relate genetic
expression with tumor response to radiotherapy.
Our data confirm that the extent of lymph node involve-
ment affects outcome. In the 54 patients submitted to
lymphadenectomy, 5-year OS, CSS and DFS were signifi-
cantly lower in patients who were N+ (p = 0.01, p = 0.01
and 0.005, respectively). Worse 5-years DFS was mainly
due to higher distant metastasis rate (p = 0.03) rather than
due to local-regional recurrence (p = 0.08) and suggests
the need of therapy that could positively impact on dis-
tant control. In fact, the standard approach for advanced
cervical cancer has been changed after 3 randomized trials
and a meta-analysis demonstrate significant benefit of
concomitant chemoradiotherapy compared to radiation
alone. This Cochrane meta-analysis have found that cispl-
atin-based chemoradiation improved overall survival,
progression free survival and was associated with a signif-
icant decrease in local and distant failure compared with
radiation alone. The prospective randomized trial GOG
#123 compared pre-operative chemoradiotherapy to pre-
operative radiotherapy and demonstrated a better out-
come for the combined treatment group (for both OS and
PFS and also improved the metastasis free survival) [12].
The question to be answered now is whether combined
pre-operative chemoradiation is better than combined
chemoradiation alone.
The impact of pathological response to radiotherapy on
outcome is debatable. Some studies with post-radiation
hysterectomy noticed, however, that patients with resid-
ual disease on cervical specimens were found to have
worse prognosis [6,34]. The biomolecular pathway are
being discovered and better-defined. If we might predict
which patients would go worse with radiation therapy
only, then, we might add hysterectomy. In our data we
found 43% CPR on the cervix, but could not demonstrate
the relation between cervical CPR and outcome (p =
0.08), possibly because of the small number of studied
specimens. Unfortunately, the GOG 123# trial has not
analyzed their results on pathological response with
chemotherapy.
Maruyama and cols [34] have addressed this subject in
their patterns of care study and have found a higher inci-
dence of local and regional recurrence in patients with
residual disease on surgical specimens. Thus, they sug-
gested that the addition of more brachytherapy to the vag-
inal vault could improve results
(EBRT→Braqui→Surgery→residual tumor on speci-
men→vaginal vault brachytherapy). On our study, of the
38 patients who had residual disease on the cervix, 11
were submitted to additional vaginal vault brachytherapy
and they did not perform better than the other 27 who
were not submitted to extra brachytherapy (p = 0.58).
In our study the time between preoperative RT and surgery
higher than 80 days was significantly associated with
complete pathological response. As we also showed that
Table 2: Crude incidence of toxicity according to the RTOG criteria.
Grade 0 1 2 3 4
Genitourinary tract Acute 57(85%) 5(7.5%) 5(75%) 0 0
Late 53(79%) 2(3%) 4(6%) 4(6%) 4(6%)
Gastrointestinal Tract Acute 37(55%) 18(27%) 12(18%) 0 0
Late 57(85%) 5(7.5%) 2(3%) 2(3%) 1(1.5%)Page 6 of 8
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important to determine the best interval between RT and
S to achieve the best results regarding local control.
Also of great importance is the fact that for exclusive radi-
otherapy the total time to complete the course of treat-
ment is determinant of outcome as shown by Ferrigno
and cols [26]. Considering that patients who receive EBRT
and reduced dose HDRB are supposed to undergo surgery
the coordination between the radiation oncologist and
the surgeon is fundamental. If the patient for any reason
is deemed surgery she has to complete the adequate dose
of HDRB in the proper length of time.
Of note is the fact that the present study has not used
LDRBT, but only HDRB. Lambin and cols [35] studied
pathological response following LDRB and found differ-
ent response rates for small variations in dose rate
employed. In a next study we intend to compare patho-
logical response between LDRB and HDRB and relate it to
their biological equivalence.
Conclusion
Time allowed between RT and surgery correlated with
pathological response. Pelvic pathological response was
associated with improved outcome. Postoperative addi-
tional HDRB did not improve therapeutic results. Treat-
ment was well tolerated.
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